InspireMD
InspireMD is a Miami-based medical device company that develops and commercializes the CGuard Prime carotid stent system, a MicroNet mesh-covered stent for stroke prevention, selling directly to hospitals and vascular specialists in the U.S. and Europe.
- Company typePublic
- Founded2005
- HeadquartersMiami, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What InspireMD does
InspireMD is a U.S.-incorporated (Delaware) medical device company headquartered in Miami, Florida, with an Israeli R&D subsidiary, focused on stroke prevention through carotid artery stenting. Its commercial product is the CGuard Prime Carotid Stent System, a dual-layer device combining an inner self-expanding nitinol frame with an outer finely woven polyethylene terephthalate (PET) MicroNet mesh covering approximately 150-180 micrometer pore size, designed to prevent plaque prolapse and embolization during and after carotid artery stenting procedures. The system also incorporates SmartFit, a conformable open-cell stent design intended to adapt to a wide range of anatomies without tapered configurations.
The company's flagship product received FDA premarket approval in June 2025 and was launched in the U.S. market in July 2025, following international commercialization under CE MDR approval. The company is building a pipeline that includes the SwitchGuard Neuro Protection System for transcarotid artery revascularization (TCAR) procedures, currently in the CGUARDIANS III pivotal study, and is pursuing a PMA supplement for its 80 cm stent for the TCAR indication.
InspireMD generates revenue through direct enterprise field sales of its hardware products to hospitals and vascular intervention centers, with go-to-market supplemented by medical conference participation, peer-reviewed clinical publications, and physician education. Customers are vascular surgeons and interventional cardiologists treating patients with carotid artery stenosis who are at high risk for carotid endarterectomy. As of Q1 2026, the company reported revenue of $3.4 million, had raised over $189 million in cumulative funding across multiple private placements and warrant exercises since 2010, and was operating with 51-100 employees.
InspireMD firmographics
Firmographics- Name
- InspireMD
- Legal name
- InspireMD, Inc.
- Website
- https://inspiremd.com
- Company type
- Public
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- InspireMD is a Miami-based medical device company that develops and commercializes the CGuard Prime carotid stent system, a MicroNet mesh-covered stent for stroke prevention, selling directly to hospitals and vascular specialists in the U.S. and Europe.
- Ownership category
- akta.pro rank
InspireMD industry classification
Industry- Product category
- Vascular Medical Devices (Carotid Stent Systems)
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)
- akta.pro secondary industries
- Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE), Interventional Cardiology (PCI/Structural Heart) (HLAKABAB)
Keywords
Where InspireMD is headquartered
LocationHeadquarters
- HQ city
- Miami
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
InspireMD business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
Revenue model
- CGuard Prime Carotid Stent System Sales: Sale of FDA-approved CGuard Prime carotid stent system and delivery components to hospitals and vascular intervention centers. Revenue generated from product sales to healthcare providers performing carotid artery stenting procedures. Q4 2025 revenue of $3.1M with 62% year-over-year increase driven by U.S. launch and international expansion.
- International Product Sales: Revenue from international markets where CGuard has CE MDR approval. CGuard EPS indicated for improving carotid luminal diameter in patients at high risk for adverse events from carotid endarterectomy.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
InspireMD product offering
Product offeringCore offering
InspireMD develops and commercializes the CGuard Prime Carotid Stent System, a dual-layer carotid stent with proprietary MicroNet mesh technology (woven PET outer layer with ~150-180 μm pore size) over a SmartFit nitinol frame, designed to prevent plaque prolapse and embolization during carotid artery stenting procedures for stroke prevention. The product is sold to hospitals and vascular intervention centers for use in patients at high risk for adverse events from carotid endarterectomy.
Product overview
InspireMD is a medical device company focused on stroke prevention through carotid artery stenting. The company offers a unified product portfolio centered on the CGuard Prime Carotid Stent System, which incorporates the proprietary MicroNet mesh technology for embolic protection. The flagship product is a dual-layer stent combining SmartFit nitinol frame technology with MicroNet mesh covering. Additional pipeline offerings include the SwitchGuard Neuro Protection System for TCAR procedures, which is currently in clinical development.
Differentiator
Problem solved
Functional benefit
Brands
- CGuard: Next-generation carotid stenting system featuring a unique dual-layer design with a finely woven MicroNet mesh covering for stroke prevention
- CGuard Prime
- SwitchGuard
- MicroNet
- SmartFit
Products and services
- CGuard Prime Carotid Stent System Dual-layer carotid stent system combining a SmartFit self-expanding nitinol open-cell frame with a MicroNet polyethylene terephthalate (PET) mesh outer covering (~150-180 μm pore size) for stroke prevention. Indicated for improving carotid luminal diameter in patients with neurological symptoms and >50% stenosis or asymptomatic patients with >80% stenosis (vessel diameters 4.8–9.0 mm) who are at high risk for adverse events from carotid endarterectomy. Sold to hospitals and vascular intervention centers performing carotid artery stenting procedures.
Quantifiable outcome
- 0.95% 30-day Death, Stroke, or MI rate - lowest of any pivotal carotid stenting study
- +3 more outcomes
Companies that use InspireMD
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles1 record
InspireMD technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
InspireMD partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Good Samaritan Hospital (TriHealth System)coreDr. Patrick Muck serves as global co-principal investigator for CGUARDIANS III pivotal study evaluating SwitchGuard Neuro Protection System for TCAR procedures. Good Samaritan Hospital part of TriHealth System.
- Washington University School of MedicinecoreDr. Patrick Geraghty serves as global co-principal investigator for CGUARDIANS III pivotal study. Academic medical center partnership for clinical research.
- OhioHealth Riverside Methodist HospitalcoreDr. D. Christopher Metzger led C-GUARDIANS pivotal trial as principal investigator at OhioHealth Riverside Methodist Hospital, Columbus, Ohio.
Scale indicators12 records
Recent moves6 records
Expansion highlights6 records
InspireMD competitors and assessment
Company assessmentBroad incumbents
- Medtronic: Medtronic offers the Mo.Ma Ultra proximal embolic protection device and broader vascular intervention portfolio referenced as a compatible accessory for CGuard procedures, and competes in carotid and neurovascular intervention as part of a much larger medtech portfolio.
- Stryker (Neurovascular): Stryker's Neurovascular division sells devices for stroke intervention (including mechanical thrombectomy and access products), serving overlapping hospital and interventional neurology customers as InspireMD's CGuard franchise.
- Edwards Lifesciences: Edwards Lifesciences is a structural heart and vascular intervention incumbent; CCO Shane Gleason previously led U.S. transcatheter heart valves marketing at Edwards, and the company operates in adjacent vascular intervention segments.
- Abbott Laboratories: Abbott's vascular division sells the Roadsaver/CASPER carotid stent system (FDA-approved Nov 2024) and Emboshield NAV6 embolic protection device — both directly competitive with InspireMD's CGuard Prime and MicroNet technology in U.S. carotid stenting.
- Boston Scientific: Boston Scientific acquired Silk Road Medical (TCAR pioneer) for ~$1.18B in 2024 and competes broadly in vascular and carotid intervention; the recent CGUARDIANS III program targets the same TCAR segment that Boston Scientific now leads.
Direct peers
- Terumo Corporation: Terumo's interventional systems division develops carotid and embolic protection products, positioning it as a direct peer in the vascular stent and embolic protection category where CGuard competes.
- W. L. Gore & Associates: Gore has historically been a meaningful player in carotid stent systems (e.g., Gore Carotid Stent) and competes with InspireMD in carotid artery stenting for high-surgical-risk patients.
Regional players
- MicroPort Scientific Corporation: MicroPort is a global cardiovascular and endovascular device company with carotid and peripheral intervention products, representing an international peer in carotid and vascular stenting.
- Cardinal Health (Cordis): Cordis, a Cardinal Health business, markets vascular access and intervention products including carotid stenting portfolios and is a former employer of InspireMD's CCO; it competes in the broader vascular intervention space.
Emerging players
- Penumbra, Inc. Penumbra is a neurovascular and vascular thrombectomy company addressing the broader stroke intervention market that includes carotid stenting, making it an adjacent peer with overlapping call points in neurovascular intervention.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
InspireMD social profiles
Digital presenceInspireMD financial estimates
Financial estimateRevenue estimate
Valuation estimate
InspireMD leadership team
Management profileNumber of profiles
Profiles13 records
InspireMD funding detail
Funding detailFunding overview
Funding rounds12 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
InspireMD M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about InspireMD
What does InspireMD do?
InspireMD develops and commercializes the CGuard Prime Carotid Stent System, a dual-layer carotid stent with proprietary MicroNet mesh technology (woven PET outer layer with ~150-180 μm pore size) over a SmartFit nitinol frame, designed to prevent plaque prolapse and embolization during carotid artery stenting procedures for stroke prevention. The product is sold to hospitals and vascular intervention centers for use in patients at high risk for adverse events from carotid endarterectomy.
Is InspireMD a public or private company?
InspireMD is a public company. It is classified as public and is currently operating.
When was InspireMD founded?
InspireMD was founded in 2005. It employs 101 to 250 people.
Where is InspireMD based?
InspireMD is headquartered in Miami, United States, in the North America region.
How does InspireMD make money?
Two revenue lines are on record. CGuard Prime Carotid Stent System Sales are the primary driver. The others are international Product Sales.
Who are InspireMD's main competitors?
Broad incumbents on record are Medtronic, Stryker (Neurovascular), Edwards Lifesciences, Abbott Laboratories and Boston Scientific. Direct peers are Terumo Corporation and W. L. Gore & Associates. Regional players are MicroPort Scientific Corporation and Cardinal Health (Cordis). Penumbra, Inc. is listed as an emerging player.
Does InspireMD have an API?
No public API is recorded for InspireMD.
What industry is InspireMD in?
InspireMD's product category is Vascular Medical Devices (Carotid Stent Systems). Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices, with a secondary code of HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy). Its NAICS code is 334510 and its SIC code is 3845.